Leo on for Oi Eer's questions to ACADIA Pharmaceuticals Inc (ACAD) leadership • Q2 2025
Question
Leo, on for Oi Eer, asked about the growth perspective for NUPLAZID and Daybue in 2026 and which pipeline programs the management team is most excited about.
Answer
Chief Commercial Officer Thomas Garner projected continued and accelerating growth for Daybue in 2026, citing low market penetration, and sustained strength for NUPLAZID, building on current momentum. EVP, Head of R&D, Elizabeth Thompson, declined to pick a 'favorite child' but highlighted the pipeline's mix of de-risked and novel biology assets. CEO Catherine Owen Adams added that five pipeline products have blockbuster potential.